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It is often stated that type 1 diabetes results from a
complex interplay between varying degrees of genetic
susceptibility and environmental factors. While agreeing
with this principal, our desire is that this Perspectives
article will highlight another complex interplay poten-
tially associated with this disease involving facets re-
lated to the gut, one where individual factors that, upon
their interaction with each another, form a “perfect
storm” critical to the development of type 1 diabetes.
This trio of factors includes an aberrant intestinal mi-
crobiota, a “leaky” intestinal mucosal barrier, and al-
tered intestinal immune responsiveness. Studies
examining the microecology of the gastrointestinal tract
have identiﬁed speciﬁc microorganisms whose presence
appears related (either quantitatively or qualitatively)
to disease; in type 1 diabetes, a role for microﬂora in the
pathogenesis of disease has recently been suggested.
Increased intestinal permeability has also been observed
in animal models of type 1 diabetes as well as in humans
with or at increased-risk for the disease. Finally, an
altered mucosal immune system has been associated with
the disease and is likely a major contributor to the
failure to form tolerance, resulting in the autoimmunity
that underlies type 1 diabetes. Herein, we discuss the
complex interplay between these factors and raise test-
able hypotheses that form a fertile area for future
investigations as to the role of the gut in the pathogen-
esis and prevention of type 1 diabetes. Diabetes 57:
2555–2562, 2008
WHY WRITE A PERSPECTIVES THAT EMPHASIZES THE
GUT?
In addition to comprising the largest surface area of the
body, the intestinal mucosa is constantly exposed to a vast
array of microbes, food antigens, and toxins. The intestinal
epithelium must discriminate between pathogenic and
nonpathogenic organisms as well as food antigens. It must
“tolerate” the commensal ﬂora that maintain mucosal
homeostasis by controlling inﬂammatory responses as
well as sensing danger signals of potentially harmful
pathogens. It is becoming increasingly clear that the nexus
of intestinal microbiota composition, the intestinal barrier,
and the mucosal immune system plays pivotal roles in the
development of a variety of allergic and autoimmune
diseases.
In the case of type 1 diabetes, evidence for a synergism
between aberrant intestinal microbiota, a “leaky” intesti-
nal mucosal barrier, and altered mucosal immunity con-
tributing to the disorder’s pathogenesis has begun to
evolve (Table 1). If these facets do indeed form important
components for the pathogenesis of type 1 diabetes, they
also offer potential targets for intervention that would
include maintenance of a nondiabetogenic microbiota,
tightening of interepithelial junctions, as well as preven-
tion of propagation of inﬂammation and autoimmunity by
nutritional or pharmacologic means. In the following sec-
tions, we will review each aspect for its physiological
function and provide evidence as to how it may form
pathogenic signiﬁcance in type 1 diabetes.
ALTERED INTESTINAL MICROBIOTA
The presence of a commensal intestinal microbiota in
infancy is critical for numerous physiologic processes
including growth, angiogenesis, optimization of nutrition,
and stimulation of various arms of the innate and adaptive
immune systems (1–4). With this, it is surprising that the
effects of intestinal microbiota on the development of type
1 diabetes remain an area subject to somewhat limited
investigation.
What does seem clear is that rodent models of type 1
diabetes, including NOD mice and related substrains, are
more likely to develop disease under speciﬁc pathogen-
free conditions (5,6). Furthermore, diabetes-prone BB rats
(BBDP) subject to Cesarean derivation have been noted to
develop accelerated disease (7). In terms of using such
information to proactively modulate diabetes formation,
the provision of antibiotics, such as fucidic acid, Colistin,
and Bactrim, in BB rats after weaning (8,9) lead to
diabetes prevention, whereas in our own efforts using the
NOD mouse, a decreased frequency of type 1 diabetes was
observed with the administration of doxycycline (10). The
speciﬁc mechanisms of how such therapies modulate
disease are unclear, but it is clear that changes in the
microbiota affect the development of autoimmune diabe-
tes in both animal models. Supporting this view, oral
probiotic administration to NOD mice was noted to induce
interleukin (IL)-10 (i.e., an anti-inﬂammatory cytokine)
production and prevented the development of type 1
diabetes (11).
Interest exists on intestinal microbiota composition, a
metric that has previously relied almost exclusively on
the quantitative cultures from feces. At this time, we are
not aware of any published studies that have demon-
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humans with or at high-risk for the development of type
1 diabetes. Furthermore, most microbial species in the
intestinal microbiota are not amenable to culture. With
the knowledge that environment inﬂuences the develop-
ment of type 1 diabetes and that the gastrointestinal
tract provides the greatest surface area for interaction
of the environment, this is an area that begs further
investigation.
Over 500 species of microbes are known to reside in the
human gastrointestinal tract (1,2). Their interaction with
the mucosal immune system, especially in the ﬁrst years of
life, may have life-long effects. As but one example,
differences in the composition of intestinal microﬂora
between healthy and allergic infants in countries with a
high and low prevalence of allergies have been noted and
precede clinical symptoms (12). Furthermore, probiotics
have been successfully used as immunomodulators in the
prevention and treatment of allergies in children (13,14),
ﬁndings indicating that commensal bacteria are not inno-
cent bystanders in humans but active players in the
shaping of the immunological network of the host. Hence,
new approaches for evaluating the interactions between
the intestinal microbiota and barrier and innate immunity
are needed.
Among the most promising molecular techniques that
have recently been developed to ﬁll this void are those that
enable detection of uncultivatable species and that are
amenable to statistical microecologic analyses. Some of
these methods target 16Ss RNA gene sequences, as they
contain signatures of phylogenetic groups and sometimes
even species (15). Other techniques apply PCR with dena-
turing or temperature gradient gel electrophoresis, ﬂuo-
rescent in situ hybridization and shotgun sequencing DNA
(16), and whole metagenomic approaches (17). These
techniques offer promise for future efforts seeking to
establish a causal link between the intestinal microbiota
and type 1 diabetes, as well as to the identiﬁcation of
aberrant microbiota that could be targeted for disease
prevention strategies.
ALTERATIONS OF INTESTINAL PERMEABILITY IN TYPE
1 DIABETES
The intestinal surface barrier is one of the most important
components of the innate immune system, separating
highly immunogenic agents in the intestinal lumen from a
highly immunoreactive submucosa. Before aberrant mi-
crobes or other antigens can affect the highly immuno-
reactive submucosa, they must transduce signals mediated
by intestinal epithelial toll-like (or similar) receptors,
traverse the intestinal epithelial barrier by either the
transcellular or interepithelial paracellar route, or inﬂu-
ence other cells possessing the capacity to traverse this
barrier (e.g., intraepithelial lymphocytes and dendritic
cells). Before describing how this system may relate to
TABLE 1
Intestinal alterations reported in patients with type 1 diabetes or in individuals at risk of type 1 diabetes
Finding Interpretation Reference
Increased absorbed ratio of ingested lactulose
and mannitol in patients with type 1
diabetes
Altered gut permeability in type 1
diabetes
Kuitunen et al. (24), Sapone et al. (25),
Secondulfo et al. (26)
Increased absorption of ingested lactulose
and mannitol in individuals with -cell
autoimmunity Altered gut permeability in pre-diabetes Bosi et al. (23)
Alterations in height and thickness of
microvilli, space between microvilli and
thickness of tight junctions Mucosal injury in type 1 diabetes Secondulfo et al. (26)
High levels of serum zonulin in patients with
type 1 diabetes
Changes in tight junctions in type 1
diabetes Sapone et al. (25)
Enhanced expression of HLA-DR and –DP,
ICAM-1, 47-integrin, IL-4, IL-1, IFN- in
small intestinal biopsy samples from
children with type 1 diabetes
Intestinal inﬂammation in children with
type 1 diabetes
Savilahti et al. (28), Westerholm-Ormio
et al. (29)
Higher density of intraepithelial CD3 and
/-cells and lamina propria CD25 cells in
type 1 diabetes
Activation of intestinal immunity in
type 1 diabetes Auricchio et al. (30)
Increase in CD3 and CD25 cells and enhanced
ICAM-1 and HLA-DR expression in small
intestinal biopsy samples cultured with
gliadin
Activation of intestinal T-cells by
gliadin in type 1 diabetes Auricchio et al. (30)
Increased expression of matrix
metalloproteinases and apoptotic cells in
small intestinal biopsy samples from
children with type 1 diabetes and
anti-transglutaminase antibodies
Prominent mucosal inﬂammation
related response in the diabetic
children positive for
transglutaminase antibodies Bister et al. (32)
Enterovirus detected in small intestinal
biopsies from patients with type 1 diabetes
Chronic or recurrent intestinal
enterovirus infections in type 1
diabetes Oikarinen et al. (42)
Low numbers of Foxp3-positive cells or
Foxp3 transcripts despite increased IL-18
transcription in small intestinal biopsy
samples from children with type 1 diabetes
No activation of intestinal regulatory
T-cells despite activation of innate
immunity in children with type 1
diabetes Tiittanen et al. (31)
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the system (Fig. 1).
Mucosal barrier cells. There are numerous cell types in
the small intestine that play a role in barrier function,
including the following.
Intestinal epithelial cells. Intestinal epithelial cells
(IECs) comprise the lining epithelium of the primitive
intestine. These cells are derived from the same undiffer-
entiated stem cell that gives rise to columnar, mucous,
goblet, enteroendocrine, and probably M-cells in the intes-
tine. The well-known function of the IEC as the major
nutritive absorptive cell should not overshadow its role in
transduction of inﬂammatory signals from luminal mi-
crobes via toll-like receptors and other signaling mecha-
nisms. Furthermore, these cells possess intercellular
interdigitations and structures that join the intestinal
epithelial cells (Fig. 1). The tight junction (i.e., zonula
occludens) is the most apical component of the junctional
complex and serves as the permeability barrier between
the external and internal milieus of the body. The tight
junction completely encircles the apical end of absorptive
cells as a belt-like band. Several transmembrane proteins
and proteins on the cytosolic leaﬂet are a part of the tight
junction; these include the claudins and occludin protein
families. Interactions of some of these proteins with the
actin cytoskeleton are a major determinant of tight junc-
tion structure and play a role in the regulation of para-
cellular permeability.
M-cells. M-cells do not have well-developed microvilli and
allow macromolecular transport, whereas the absorptive
enterocyte has better-developed microvilli. M-cells are
specialized for delivering foreign antigens and microorgan-
isms to organized lymphoid tissues within the mucosa of
the small and large intestines. They are thought to play a
major role in speciﬁc immunity to luminal antigens. Little
is known about relative contributions of these cell types in
the pathogenesis of type 1 diabetes, but as will be dis-
cussed later, lines of evidence are pointing toward in-
creased paracellular permeability playing a role.
Goblet cells. Goblet cells are specialized mucus-secretory
cells found throughout the intestine. Intestinal mucus is a
complex gel that covers the surface of the villous epithe-
lium and contributes signiﬁcantly to cytoprotection, offer-
ing many ecological advantages for the microbiota.
Paneth cells. Paneth cells represent one of the four major
epithelial cell lineages in the small intestine and are the
only lineage that migrates downward into the crypt base
after originating in the crypt stem cell region. The location
of Paneth cells adjacent to crypt stem cells suggests that
they play a critical role in defending epithelial cell re-
newal. In response to pathogen attack, the Paneth cells
secrete a wide spectrum of antimicrobial peptides against
gram-negative and gram-positive bacteria, fungi, protozoa,
and viruses.
Intraepithelial lymphocytes. Intraepithelial lympho-
cytes (IELs) are located at the basolateral side of the
epithelial layer. Here they are exposed to a wide range of
food and microbial antigens. One well-established func-
tion of IELs is their ability to protect the host from
invasion by microorganisms that enter through the gastro-
intestinal tract. One subtype, the  intestinal epithelial
lymphocytes, are also at the mucosal interface and appear
to play a key role in maintaining peripheral tolerance (18).
HOW GUT LEAKINESS MAY INFLUENCE TYPE 1
DIABETES
Multiple tight junction integral proteins have been identi-
ﬁed (Fig. 1), including occludin and members of the
claudins family; a group of at least 20 tissue-speciﬁc
proteins are the major sealing proteins that locate between
intestinal epithelial cells (19). The claudins, a family of
integral tight junction proteins, form ion-selective pores
within the tight junction strands, whereas occludin and
junctional adhesion molecule may have an adhesive and/or
signal transducing function as they interact with various
cytosolic complexes (19). In the intestinal epithelium,















FIG. 1. Constituents of the intestine.
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The combination of these two proteins functioning to-
gether performs the major “gatekeeper” or barrier function
of the tight junction. These sealing proteins, both trans-
membrane proteins, interact with cytoplasmic proteins
that function as adaptors between the tight junction
proteins along with actin and myosin contractile elements
within the cell. Acting together, they open and close the
paracellular junctions.
Our previous studies using the permeability markers
lactulose and mannitol veriﬁed that BBDP rats, before the
onset of type 1 diabetes, exhibit a highly permeable
intestine associated with low levels of intestinal claudin, a
major intercellular tight junction protein (20). Intestinal
myeloperoxidase activities and goblet cell density are also
higher in the diabetes-prone rats than in controls, support-
ing the notion of an early intestinal inﬂammatory re-
sponse. Our studies (20), as well as those of Meddings
et al. (21) and Graham et al. (22), show that not only is
enteropathy a consistent feature in the BBDP rat, but it
precedes the onset of insulitis and appears to be due to
mechanisms distinct from those that cause type 1 diabe-
tes. More importantly, this is not a phenomenon that
occurs only in rodent models of diabetes, as very recent
studies have noted that humans with a propensity to
develop type 1 diabetes as well as other autoimmune
diseases possess an abnormal intestinal barrier; the so
called “leaky gut” (20,21). Namely, intestinal samples from
individuals at risk for (23) or already diagnosed with type
1 diabetes demonstrated abnormalities identiﬁed with
sugar permeability tests (24–26) and associated with in-
terepithelial junctions on electron microscopy (26). These
ﬁndings are entirely consistent with the concept that a
leaky intestine in the setting of type 1 diabetes would
allow for greater exposure of the intestinal immune sys-
tem to antigens (Fig. 2).
Although the mechanisms leading to a “leaky gut” before
the development of type 1 diabetes remain largely under-
stood, studies aimed at altering intestinal tight junctions
have been initiated. Fasano and colleagues (27) found high
levels of the protein zonulin, which has been observed to
increase intestinal permeability in rats prone to develop
diabetes, and have initiated studies designed to counteract
the effects of zonulin. High serum levels of zonulin that
correlated with increased ratios in sugar permeability
testing have also been noted for patients with type 1
diabetes (25). Other modulators of tight junction proteins
(e.g., certain probiotics and short-chain fatty acids such as
butyrate) may also play a role in modulation of “intestinal
leakiness.”
ALTERED INTESTINAL IMMUNITY
The third facet related to the gut that may be key to type
1 diabetes development relates to intestinal immunity. Of
the three, this is the area perhaps subject to the most
investigation in settings of type 1 diabetes. To provide a
unique glimpse into this area, we and others have
investigated markers of immune activation in small
intestinal biopsies taken from children with type 1
diabetes that failed to show signs of celiac disease.
Speciﬁcally, these subjects did not demonstrate signs of
celiac disease, they were negative for transglutaminase
antibodies, and their intestinal morphology in terms of
celiac disease–associated inﬂammation was normal.
These studies noted enhanced expression of antigen-
presenting HLA class II molecules (Fig. 3), increased
expression of intracellular adhesion molecule (ICAM)-1
on epithelium, and 47-integrin on cells of the lamina
propria (28,29). In line with these ﬁndings, activation of
the cytokine network was also demonstrated in the
lamina propria. Speciﬁcally, increased densities of cells
FIG. 2. Hypothetical model of the contribution of various gut components to the pathogenesis of type 1 diabetes.
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as increased numbers of interferon- mRNA–expressing
cells, were observed in patients with type 1 diabetes.
The second effort to address this question, involving
small intestine biopsies from type 1 diabetic patients,
demonstrated high numbers of CD25-positive cells, as
well as increased numbers of intraepithelial CD3- and
/-positive cells, in lamina propria (30). Interestingly,
the ﬁndings of intestinal immune activation were not
restricted to individuals with the HLA DQ2 allele (i.e.,
the HLA risk allele found in 90% of patients with celiac
disease). Thus, the altered intestinal immunity in type 1
diabetes appears to represent a separate entity from
celiac disease.
Very recent efforts have addressed questions related to
regulatory T-cells, which are thought to be vital to the
FIG. 3. Immunoperoxidase stainings for HLA-DR (A and B) and HLA-DP (C and D) in jejunal biopsy specimens from a healthy control (A and C)
and from a type 1 diabetic patient with normal jejunal mucosa (B and D). Intensive, positive HLA-DR staining is seen throughout the epithelial
cells of the villi and also in many crypt cells in the type 2 diabetic specimen (B), whereas the control specimen shows only faint HLA-DR staining
in the apical parts of the epithelial cells at the tip of the villi (A). The biopsy specimen from a control patient treated with HLA-DP antibody shows
scattered positive granules in the apical parts of the epithelial cells at the tip of the villi (C), whereas strong positive staining is seen throughout
the villous epithelial cells in the specimen from a type 1 diabetic patient (D). No positive staining is seen with either HLA-DR or HLA-DP in crypt
cells in the control specimen (A and C). AEC-hematoxylin stain, original magniﬁcation 50. (Please see http://dx.doi.org/10.2337/db08-0331 for
a high-quality digital representation of this ﬁgure.)
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ulation and are marked by the transcription factor Foxp3.
Speciﬁcally, these efforts included examination of Foxp3-
positive cells in small intestinal biopsies from children
with type 1 diabetes as well as from those with celiac
disease (31). In children with type 1 diabetes, the densities
of Foxp3-positive cells were low and did not show activa-
tion of Foxp3 transcripts. This was in contrast to celiac
disease, where related inﬂammation involving Foxp3 ex-
pression was noted. The absence of intestinal Foxp3
activation in type 1 diabetes provides a strong rationale for
further investigation regarding the whether impaired reg-
ulatory mechanisms could explain the subclinical intesti-
nal immune activation and altered responses to dietary
antigens.
In terms of how this altered immunity may ﬁnd its
genesis, another potential candidate is matrix metallopro-
teinases (MMPs), enzymes produced by several different
cell types and released in response to inﬂammation. MMPs
participate in the remodeling of extracellular matrix, and
when their function goes uncontrolled, they have been
noted for the ability to induce tissue injury. When MMP
proﬁles and apoptotic characteristics were studied in a
group of children positive for transglutaminase antibodies,
the subgroup of children with type 1 diabetes showed
higher expression of MMPs and increased proportion of
apoptotic mucosal cells than children without type 1
diabetes (32). Taken collectively, these ﬁndings performed
in small intestinal biopsy samples from type 1 diabetic
patients directly implicate altered activation of both innate
and adaptive immune cells in the intestinal mucosa and
provide a new focus on the potential role of intestinal
immunity in the pathogenesis of human type 1 diabetes.
With all of this in mind, the question is, why would this
occur?
Triggers of intestinal immunity. In the association of
increased intestinal permeability and inﬂammation, al-
tered responses to food and microﬂora-derived antigens
often develop. It is however indistinguishable whether the
aberrant response to food or microbial antigen is the
trigger of intestinal inﬂammation and increased permeabil-
ity or vice versa.
Regarding type 1 diabetes and aberrant responses to
food, enhanced immunity to wheat and cow milk have
been reported in type 1 diabetic patients as well as in their
relatives (33,34). Interestingly, wheat gliadin stimulation
of small intestinal biopsies from children with type 1
diabetes noted an increase in intraepithelial CD3 cell
numbers in lamina propria CD25-positive cells and en-
hanced expression of ICAM-1 and HLA-DR. In contrast, no
such activation of T-cells was seen in biopsy samples
taken from healthy children (30). This suggests that al-
tered response to wheat gliadin in children with type 1
diabetes may contribute to the intestinal inﬂammation. It
is possible that the HLA-DQ2 and -DQ3 alleles often
present in type 1 diabetic and celiac disease patients are
responsible for the presentation of wheat gliadin–derived
antigens and for the induction of inﬂammation, which
however does not lead to full-blown celiac disease in these
cases. Some studies suggest that early exposure to wheat-
containing food in infancy increases the risk of -cell
autoimmunity (35,36), which could be explained by induc-
tion of intestinal inﬂammation, as suggested by both
human (30) and experimental (37) studies. In individuals
at risk of type 1 diabetes who had -cell autoantibodies,
insulin response to glucose improved after 6 months of
gluten-free diet, but no changes in the autoimmune re-
sponse were seen (38). Thus, there is no evidence that
elimination of wheat would decrease the intestinal im-
mune activation in type 1 diabetes. Indeed, one could
argue that the aberrant immune responses to several
dietary antigens noted for subjects with type 1 diabetes,
including cow milk–derived proteins, supports the notion
that the altered responsiveness is not limited to wheat but
may rather be non–antigen-speciﬁc phenomenon in the gut
of those with type 1 diabetes.
As far as microbial stimulators of intestinal inﬂamma-
tion, enterovirus and rotavirus infections have been linked
to development of -cell autoimmunity (39,40), with some
studies demonstrating enterovirus antigens in pancreatic
-cells of patients with type 1 diabetes (41). The role of
enteroviruses as candidate triggers of intestinal immunity
in type 1 diabetes has been suggested by a recent study in
which enteroviral-derived protein VP1 and enterovirus-
speciﬁc RNA was demonstrated more frequently in small
intestinal biopsy samples from type 1 diabetic patients
compared with those from nondiabetic patients (42).
These ﬁndings should be considered preliminary because
the number of patients was small and all patients were
studied years or decades after diagnosis of type 1 diabetes.
Given that activation of immunity as a response to entero-
virus CVB4 is decreased in peripheral blood mononuclear
cells from children with type 1 diabetes (43), this impaired
immunity and poor support of cytotoxic mechanisms
important for virus clearance could explain the ﬁndings of
enterovirus in the intestine even years after diagnosis of
type 1 diabetes. The observation, if conﬁrmed, suggests
that either chronic enterovirus infection in type 1 diabetes
or predisposition to recurrent enterovirus infections,
rather than accidental role of enterovirus infections, is
responsible for the induction of -cell autoimmunity.
Indeed, enteral infections are known to change the cyto-
kine pattern (44) and increase the permeability of the gut
(45), which in some cases may lead to enhanced immunity
to food proteins. On the other hand, the demonstration of
enterovirus in the intestine of patients with type 1 diabetes
could be secondary to the altered mucosal immunity
associated with the disease itself.
Mucosal immunity and tolerance. While the deﬁnition
of immunological “tolerance” is often subject to debate, at
one level it denotes the absence of a detectable functional
immune response. With rare exception, most individuals
develop immune systems that are tolerant to self, as well
as toward substances they ingest. However, in the setting
of type 1 diabetes, it is this loss of immunological toler-
ance that leads to the autoimmunity ascribed with the
disease (46).
At this time, however, our understanding of the relation-
ship between intestinal microbiota, the “leaky intestine” in
diabetes-prone animals and humans, and tolerance is
poorly understood. One pathway (Fig. 2) could involve the
association of a highly permeable intestine that permits
the inappropriate passage of intestinal contents that, in the
presence of a certain microbiota, diminishes tolerance to
self via altered regulatory T-cells. In support of this notion,
recent work from our laboratories using BB rats demon-
strate long-term differences in pro- and anti-inﬂammatory
cytokine/chemokine patterns between animals fed using
their own mother’s milk versus formula (47). Whether
there is any relationship between this ﬁnding and differ-
ences in intestinal microbiota under the different feeding
conditions remains speculative.
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commensal microbiota closely corresponds to the regula-
tory and cytotoxic T-cell systems (48,49). This is the basis
of the “old friends” hypothesis, which states that the
presence of normal microbes (i.e., old friends) stimulates
a low-grade upregulation of regulatory T-cells that pro-
duce IL-10 and transforming growth factor-, which in
turn diminishes the effects of proinﬂammatory processes
(48). In addition to decreasing a response that would
eliminate the “old friends,” this regulatory response would
also result in maintenance of tolerance to self. This is
likely to be one of the critical mechanisms underlying the
beneﬁts of maintaining gastrointestinal commensal micro-
organisms as well as supplementation with probiotics. In
infants with a family history of allergy, probiotics that
protected from atopic eczema induced low-grade inﬂam-
mation characterized by IL-10 upregulation (13). Accord-
ingly, the administration of certain antibiotics and or
probiotics may affect the development of type 1 diabetes
by altering the balance of gut microbiota toward either a
tolerogenic or nontolerogenic state, depending on the
intestinal microbes present. Dietary factors, especially
those during infancy when new foreign proteins are intro-
duced into the diet, modulate the intestinal microbiota
(50). In NOD mice, diabetes-preventive gluten free–diet
has been shown to modulate microbiota (51). It is notable
that dietary interventions may thus not only modulate the
immune response to dietary exposure but also immunity in
general by changes in microbiota and permeability. The
interaction of tolerance, microﬂora, and permeability was
demonstrated when probiotics given to children with
atopic dermatitis resulted in a decrease of the intestinal
permeability and alleviated the symptoms of dermatitis
(52).
As noted earlier, autoimmune insulitis may result from
dysregulated oral tolerance to dietary antigens combined
with increased intestinal inﬂammation and permeability in
genetically predisposed individuals. For example, bovine
insulin, a cow milk protein, has been hypothesized as a
trigger of type 1 diabetes autoimmunity (53). Bovine
insulin may sensitize intestinal T-cells early in life to later
participation in the autoimmune destruction of insulin-
secreting -cells (53). The activation of luminal antigen-
speciﬁc T-cells in pancreatic lymph nodes has been
demonstrated in experimental animal models (54). In NOD
mice, the lymphocytes inﬁltrating the islets express the
gut-homing receptor -4-7-integrin, and the endothelium
in the insulitis display the ligand MadCam-1 (55,56). The
lymphocytes from intestine may therefore circulate be-
tween the pancreas and gut, or dendritic cells may trans-
port luminal antigens for presentation in the pancreatic
lymph nodes. These ﬁndings provide an immunological
link between dietary antigens and insulitis, which has been
earlier observed as modulation of diabetes outcome by
dietary manipulation in animal models. The Trial to Re-
duce IDDM in the Genetically at Risk (TRIGR) study is
currently testing the elimination of cow milk proteins and
the use of hydrolyzed formula during the ﬁrst months of
life in children at genetic risk of type 1 diabetes for the
purpose of preventing -cell autoimmunity. The trial is
based on encouraging results from a pilot study in which a
50% reduction of the -cell autoimmunity was observed in
children who received hydrolyzed formula versus those
who received ordinary cow milk–based formula (57). This
intervention may have multiple actions that modulate the
development of -cell autoantibodies. The intervention
may alter the composition of intestinal microbiota, pro-
mote tolerance by diminishing intestinal permeability and
inﬂammation, or modulate immune response to bovine
insulin by delaying exposure until the time of normal
intestinal maturation.
FUTURE DIRECTIONS
Clearly, much work remains in terms of understanding the
role of the gut in type 1 diabetes development. Despite
numerous studies showing health beneﬁts of probiotics,
the enthusiasm for their application as well as other means
to alter the intestinal microbial ecosystem in the preven-
tion of type 1 diabetes needs to be tempered due to the
current lack of knowledge of the normal developing
intestinal microbiota, in addition to questions as to how it
affects the developing immune system. Future studies
using newly developed techniques to evaluate intestinal
microbiota, coupled with the rapidly emerging ﬁelds of
proteomics and metabolomics, are certainly needed. In-
deed, when used to evaluate the intestinal barrier, we
believe the end result will provide not only important
insights toward the pathogenic cascade that leads to type
1 diabetes but also strategies for prevention of type 1
diabetes. Finally, the role of gut as modulator of -cell
autoimmunity, and/or as the place for initiation of -cell
autoimmunity, should provide new understanding of the
changing incidence of type 1 diabetes at different times
and in different populations.
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